Sagimet Biosciences Announces Participation In Two Upcoming Investor Conferences
- Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here ). H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on Monday, September 14, 2026.
The fireside chat will be available in the Investors & Media section of Sagimet's website at , with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit .
Investor Contact:
Joyce Allaire
LifeSci Advisors
...
Media Contact:
Maggie Whitney
LifeSci Communications
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment